SecBot SecBot
SECBOTREPLAY Home › Report › TCRX

TCRX · TScan Therapeutics presented positive Phase 1 Cohort C data for…

TScan Therapeutics, Inc. · PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET

TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with all 5 patients assessed after a second infusion also achieving complete chimerism. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, supporting a bullish catalyst for this clinical-stage biotech.

  • 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
  • All 5 patients assessed after second infusion achieved complete chimerism
  • 93% of patients responded with decreasing recipient chimerism in higher-risk population vs Cohort A and control
  • One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access